'Amgen Reports First Clinical Data On New Targeted Cancer Therapy' - Stat News
Portfolio Pulse from Benzinga Newsdesk
Amgen has presented preliminary results from its first study of an experimental pill that selectively blocks the PRMT5 enzyme in cancer cells, showing five partial responses from 31 evaluable patients. This follows the announcement that a rival PRMT5 inhibitor developed by Mirati Therapeutics factored into Bristol Myers Squibb's decision to acquire the company.
October 13, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's experimental cancer pill shows promise in early study, potentially boosting the company's position in the cancer therapy market.
The positive preliminary results from Amgen's first study of its experimental cancer pill could potentially boost the company's stock as it indicates progress in their research and development efforts. This could strengthen their position in the cancer therapy market.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Bristol Myers Squibb's decision to acquire Mirati Therapeutics, a developer of a rival PRMT5 inhibitor, could potentially strengthen its position in the cancer therapy market.
Bristol Myers Squibb's decision to acquire Mirati Therapeutics, a company developing a rival PRMT5 inhibitor, could potentially strengthen its position in the cancer therapy market. This could have a positive impact on its stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 50